Discover

News & Info

Trade

LongbridgeAI

Quote List Quote List

Bridgebio Pharma(BBIO.US)

Event Tracking

Mar31

Assenagon Asset Management S.A. Significantly Reduces Holdings in BridgeBio Pharma

07:33

Mar30

BridgeBio Reveals Long-Term Data on Acoramidis for Cardiomyopathy

15:34

BridgeBio Submits NDA for Limb-Girdle Muscular Dystrophy 2I/R9 Drug BBP-418

11:33

Mar23

BridgeBio to Present Acoramidis Phase 3 Trial Data at Annual Scientific Meeting

11:32

Mar11

BridgeBio Reports Mid-Term Results of Phase III FORTIFY Trial for BBP-418 in Limb-Girdle Muscular Dystrophy 2I/R9

18:00

Mar6

BridgeBio Pharma Director Andrea Ellis Sells Company Shares

22:01

Schedules & Filings

Schedules

Filings

Feb24

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 154.18 M, Net Income -192.86 M, EPS -0.9964

Oct29

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 120.7 M, Net Income -182.74 M, EPS -0.9525

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 110.57 M, Net Income -181.9 M, EPS -0.9547

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

Bridgebio Pharma(BBIO.US)

Bridgebio Pharma Stock Performance Chart